This software bot accelerates and streamlines the scheduling of hundreds of thousands of patient appointments to receive the two-shot vaccine for COVID-19.
Clalit Health Services, the largest healthcare maintenance organization in Israel, has already used the Kryon V-Bot to schedule more than 100,000 vaccine appointments per day.
Israel leads the world in COVID vaccinations and having already vaccinated 30% of its eight m citizens.
The logistical problems facing healthcare organizations attempting a controlled COVID-19 vaccine roll-out are astounding.
Many hospitals, healthcare providers and HMOs receive vaccines with little notice, placing enormous stress on support staff to schedule last minute appointments and use every available dose.
By automating scheduling based on eligibility criteria, the burden is lifted allowing them to focus on areas that require a human touch, like patient care and service.
Kryon is offering the V-Bot to all healthcare providers to expedite the required double-appointment setting. The purchase of Kryon V-Bot includes an unlimited amount of software bots to assist in the mass scheduling.
Further, Kryon will also customize the automation workflow of an organization's patient scheduling process based on an individual organization's structure and needs.
Kryon is in enterprise automation, offering the only platform on the market which encompasses both Process Discovery technology and Robotic Process Automation (RPA).
The Kryon Full-Cycle Automation solution maximizes ROI by 352% according to Forrester Research and cuts RPA implementation time by up to 80%.
Powered by proprietary AI technology, Kryon Process Discovery automatically generates a comprehensive picture of business processes, evaluates them, and recommends which ones to automate.
Kryon offers desktop-based attended RPA, virtual-machine-based unattended RPA, or a hybrid combination of both. The company's award-winning suite is used by enterprises worldwide, including AIG, Allianz, Deutsche Telekom, EY, Ferring Pharmaceuticals, HP, Microsoft, Santander Bank, Singtel, Verizon, and Wyndham Hotel Group.
Viatris receives Japanese approval for WAKIX in narcolepsy and sleep apnoea
WHO identifies SynAct Pharma's resomelagon among six dengue drug candidates
Japan approves subcutaneous Leqembi formulation for early Alzheimer's disease
Japan approves Lundbeck's eptinezumab for preventive migraine treatment
Skyhawk Therapeutics reports final results from Phase 1/2 trial in Huntington's disease
GSK to acquire trispecific T cell-engager from Chimagen for multiple myeloma
Kelun-Biotech publishes phase III data for trastuzumab botidotin in HER2-positive breast cancer
FDA grants priority review to Takeda's zasocitinib application for plaque psoriasis
Armata Pharmaceuticals announces receipt of FDA Breakthrough Therapy Designation for AP-SA02
AstraZeneca's Etcamah misses primary endpoint in Phase III breast cancer trial
GSK reports positive Jideytro data supporting potential first-line lung cancer use
Eloxx Pharmaceuticals commences Phase 2b study of exaluren
Akeso presents positive results from registrational Phase III study of ivonescimab
FDA grants Priority Review to Genentech's Enspryng for MOGAD